Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular...
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
biotechnology
stem cells
pharmaceuticals
ASX
innovation
Company Overview
AI-generated company summary
Mesoblast is a leader in the development of innovative cellular medicines based on its proprietary mesenchymal lineage adult stem cell technology. The company focuses on developing treatments for inflammatory diseases, cardiovascular diseases, and orthopedic conditions. Mesoblast's unique value lies in its extensive intellectual property portfolio and its ability to manufacture allogeneic cellular medicines at scale.
Company History
Founded in 2004, Mesoblast has grown to become a global leader in regenerative medicine. The company was initially focused on developing treatments for orthopedic conditions but has since expanded its pipeline to include a range of inflammatory and cardiovascular diseases. A major milestone was the acquisition of Angioblast Systems in 2010, which significantly expanded its product pipeline. Mesoblast has also formed strategic partnerships with leading pharmaceutical companies to advance its clinical programs.
Competitive Advantages
Mesoblast's competitive advantages include its proprietary mesenchymal lineage adult stem cell technology, which is protected by a robust intellectual property portfolio. The company also benefits from its scalable manufacturing processes, allowing for the production of allogeneic cellular medicines. Additionally, Mesoblast's strategic partnerships with leading pharmaceutical companies enhance its market reach and clinical development capabilities.
Risk Factors
•Regulatory approval challenges
•High R&D costs
•Market competition
Recent Developments
Last 6 months
In the past six months, Mesoblast has advanced its clinical trials for its lead product candidates, including remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company has also strengthened its financial position through strategic partnerships and capital raising activities.
Key People
Leadership team at Mesoblast
SI
Silviu Itescu
CEO
Silviu Itescu is the founder and CEO of Mesoblast. He has extensive experience in stem cell research and has been instrumental in advancing the company's clinical programs.
JR
Joseph R. Swedish
CFO
Joseph R. Swedish serves as the CFO of Mesoblast, bringing over two decades of financial leadership experience in the healthcare sector.
Financial Reports
25 reports available
Annual Report to Shareholders
Annual ReportOct 27, 2025via asx_announcements
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly ReportOct 20, 2025via asx_announcements
Preliminary Final Report including Appendix 4E
Annual ResultsAug 29, 2025via asx_announcements
Annual Financial Results Presentation
Annual ReportAug 29, 2025via asx_announcements
MSB Annual Financial Results and Operational Update
Annual ReportAug 29, 2025via asx_announcements
Mesoblast 2025 Full Year Financial Results Webcast
Full Year ResultsAug 27, 2025via asx_announcements
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly ReportJul 18, 2025via asx_announcements
Quarterly Activities/Appendix 4C Cash Flow Report
Quarterly ReportApr 30, 2025via asx_announcements
Corporate Presentation and Half Year Financial Results
Half Year ResultsFeb 27, 2025via asx_announcements
Half Year Report and Accounts (including Appendix 4D)
Half Year ResultsFeb 27, 2025via asx_announcements
